Vioxx: Lessons for health Canada and the FDA;Le Vioxx: Leçons pour Santé Canada et la FDA

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 1, 2005, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; NEW DRUG; PROSTACYCLIN; ROFECOXIB;

CARDIOTOXICITY; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE ORGANIZATION; HEART INFARCTION; HUMAN; PRESCRIPTION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STROKE;

EID: 12344322910     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.045206     Document Type: Editorial

References (4)

1. Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004;171(9):1027-8.
2. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet [serial online]. November 5, 2004 Available: http://image.thelancet.com/extras/ 04art10237web.pdf (accessed 2004 Nov 26).
3. Barratt A, Wyer PC, Hatala R, McGinn T, Dans AL, Keitz S, et al. Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171(4):353-8.
4. Laupacis A, Paterson JM, Mamdani M, Rostom A, Anderson GM. Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach. CMAJ 2003;169(11):1167-70.